T-Cell Lymphomas - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 143 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

T-Cell Lymphomas - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'T-Cell Lymphomas - Pipeline Review, H2 2014', provides an overview of the T-Cell Lymphomas's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for T-Cell Lymphomas, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for T-Cell Lymphomas and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of T-Cell Lymphomas
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for T-Cell Lymphomas and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the T-Cell Lymphomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the T-Cell Lymphomas pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for T-Cell Lymphomas
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding T-Cell Lymphomas pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
T-Cell Lymphomas Overview 8
Therapeutics Development 9
Pipeline Products for T-Cell Lymphomas - Overview 9
Pipeline Products for T-Cell Lymphomas - Comparative Analysis 10
T-Cell Lymphomas - Therapeutics under Development by Companies 11
T-Cell Lymphomas - Therapeutics under Investigation by Universities/Institutes 13
T-Cell Lymphomas - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
T-Cell Lymphomas - Products under Development by Companies 17
T-Cell Lymphomas - Products under Investigation by Universities/Institutes 18
T-Cell Lymphomas - Companies Involved in Therapeutics Development 19
arGEN-X BV 19
Bristol-Myers Squibb Company 20
Celgene Corporation 21
Cell Medica Limited 22
Infinity Pharmaceuticals, Inc. 23
Karyopharm Therapeutics, Inc. 24
Kyowa Hakko Kirin Co., Ltd. 25
Nippon Kayaku Co., Ltd. 26
Novartis AG 27
Ono Pharmaceutical Co., Ltd. 28
Onyx Pharmaceuticals, Inc. 29
Pharma Mar, S.A. 30
Pharmacyclics, Inc. 31
Seattle Genetics, Inc. 32
Sigma-Tau S.p.A. 33
T-Cell Lymphomas - Therapeutics Assessment 34
Assessment by Monotherapy Products 34
Assessment by Target 35
Assessment by Mechanism of Action 37
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 43
ARGX-110 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
BMS-906024 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
brentuximab vedotin - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
carfilzomib - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Cell Therapy to Target CD38 for cancer - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
CMD-003 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Drugs for T-Cell Lymphoma - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Drugs to Antagonize PDGFR-Beta for T-Cell Lymphomas - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
duvelisib - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
IDD-003 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
lenalidomide - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
luminespib - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
mogamulizumab - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
nivolumab - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
NK-314 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
PCI-34051 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
pegaspargase - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
plitidepsin - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
selinexor - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
T-Cell Lymphomas - Recent Pipeline Updates 85
T-Cell Lymphomas - Dormant Projects 127
T-Cell Lymphomas - Discontinued Products 128
T-Cell Lymphomas - Product Development Milestones 129
Featured News & Press Releases 129
Jun 30, 2014: Reapplication Seeking Approval for Additional Indication for ATL of Mogamulizumab 129
Feb 10, 2014: Change to Supplemental Application Seeking Approval of Additional Indication for Mogamulizumab 129
Jan 23, 2014: Infinity Reports Phase 1 Data of IPI-145 at Sixth Annual T-Cell Lymphoma Forum 130
Jul 19, 2013: Application Seeking Approval for Additional Indication for ATL, PTCL and CTCL of Mogamulizumab 131
Jun 24, 2013: Infinity Pharma Reports Phase I Data Showing Encouraging Clinical Activity Of IPI-145 Across Broad Range Of Blood Cancers At 12th ICML 132
Jun 02, 2013: Seattle Genetics Announces Presentation Of Adcetris Clinical Development Programs At ASCO Annual Meeting 2013 134
Jun 02, 2013: Infinity Pharma Reports Presentation Of Updated Phase I Data Of IPI-145 In Chronic Lymphocytic Leukemia At ASCO Annual Meeting 135
May 15, 2013: Infinity Pharma Announces Presentation Of Clinical Data On IPI-145 At ASCO 2013 And 12th International Conference On Malignant Lymphoma 137
Jan 24, 2013: Seattle Genetics And Millennium Initiate Global Phase III Clinical Trial Of Adcetris In Front-line CD30-Expressing Mature T-Cell Lymphoma 139
Dec 10, 2012: Infinity Pharma Reports IPI-145 Phase I Data Showing Clinical Activity In B-Cell And T-Cell Malignancies At ASH Annual Meeting 140
Appendix 142
Methodology 142
Coverage 142
Secondary Research 142
Primary Research 142
Expert Panel Validation 142
Contact Us 143
Disclaimer 143

List of Tables
Number of Products under Development for T-Cell Lymphomas, H2 2014 9
Number of Products under Development for T-Cell Lymphomas - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Number of Products under Investigation by Universities/Institutes, H2 2014 13
Comparative Analysis by Late Stage Development, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Development, H2 2014 16
Products under Development by Companies, H2 2014 17
Products under Investigation by Universities/Institutes, H2 2014 18
T-Cell Lymphomas - Pipeline by arGEN-X BV, H2 2014 19
T-Cell Lymphomas - Pipeline by Bristol-Myers Squibb Company, H2 2014 20
T-Cell Lymphomas - Pipeline by Celgene Corporation, H2 2014 21
T-Cell Lymphomas - Pipeline by Cell Medica Limited, H2 2014 22
T-Cell Lymphomas - Pipeline by Infinity Pharmaceuticals, Inc., H2 2014 23
T-Cell Lymphomas - Pipeline by Karyopharm Therapeutics, Inc., H2 2014 24
T-Cell Lymphomas - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2014 25
T-Cell Lymphomas - Pipeline by Nippon Kayaku Co., Ltd., H2 2014 26
T-Cell Lymphomas - Pipeline by Novartis AG, H2 2014 27
T-Cell Lymphomas - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014 28
T-Cell Lymphomas - Pipeline by Onyx Pharmaceuticals, Inc., H2 2014 29
T-Cell Lymphomas - Pipeline by Pharma Mar, S.A., H2 2014 30
T-Cell Lymphomas - Pipeline by Pharmacyclics, Inc., H2 2014 31
T-Cell Lymphomas - Pipeline by Seattle Genetics, Inc., H2 2014 32
T-Cell Lymphomas - Pipeline by Sigma-Tau S.p.A., H2 2014 33
Assessment by Monotherapy Products, H2 2014 34
Number of Products by Stage and Target, H2 2014 36
Number of Products by Stage and Mechanism of Action, H2 2014 38
Number of Products by Stage and Route of Administration, H2 2014 40
Number of Products by Stage and Molecule Type, H2 2014 42
T-Cell Lymphomas Therapeutics - Recent Pipeline Updates, H2 2014 85
T-Cell Lymphomas - Dormant Projects, H2 2014 127
T-Cell Lymphomas - Discontinued Products, H2 2014 128